Rebound thrombosis within 24 hours after interruption of therapy with rivaroxaban-Reference-Cited by-同舟云学术

Rebound thrombosis within 24 hours after interruption of therapy with rivaroxaban

Published:2016-06 Issue: Volume:212 Page:235-236
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Bakhit Ahmed,Selim Ahmed,Fatima Urooj,Dahhan Ali

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N. Engl. J. Med.,2011

2. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct factor Xa inhibitor;Perzborn;J. Thromb. Haemost.,2005

3. Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation

4. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence;Genewein;Br. J. Haematol.,1996

5. United States Food and Drug Administration. XARELTO (Rivaroxaban) tablets. http://www.fda.gov/safety/medwatch/safetyinformation/ucm367392.htm. (Accessed February 6, 2016).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design;Cardiovascular Revascularization Medicine;2024-06

2. Cavitary Pulmonary Infarction in a Case of Pulmonary Embolism After Successful Vascular Recanalization;Cureus;2019-10-24

3. Performing diagnostic radial access coronary angiography on uninterrupted direct oral anticoagulant therapy: a prospective analysis;Open Heart;2019-05

4. “Rebound” hypercoagulability after interruption of anticoagulation in patients with atrial fibrillation;International Journal of Cardiology;2018-11

5. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2);Thrombosis Research;2018-02